Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study

E. Rubinstein, S. K. Cammarata, T. H. Oliphant, R. G. Wunderink, J. Labrooy, J. L. Moran, B. Richards, D. Grimard, S. J. Landis, C. Rotstein, E. Chavez, R. Northland, V. Triantafilo, P. Vasquez, V. Kolek, M. Kucera, P. Reiterer, I. Weidenhoffer, C. Andrews, I. McLarenM. Street, T. Ali-Malkkilä, J. Heikkinen, P. Kairi, M. Valtonen, B. Georges, L. Holzapfel, A. Leon, C. D. Martin, P. Maurette, J. F. Muir, M. Ossart, B. Veber, J. Lukacs, G. Nagy, Z. Rott, R. Raz, K. Riesenberg, A. Yinnon, M. Molinari, G. Castro, G. Fabian, M. Gaca, L. Krawczyk, J. Malolepszy, R. Szulc, L. Wolowicka, A. G. Chuchalin, T. Fedorova, I. M. Kakhnovskii, V. G. Novozhenov, A. I. Sinopalnikov, J. G. Kilian, W. L. Michell, A. W. Sturm, J. Viljoen, R. Wood, J. M. Pueyo, M. Soler-Obradors, I. M. Baird, M. C. Birmingham, H. S. Bjerke, M. A. Brown, S. J D Chow, R. K. Daniels, T. Dickey, A. El-Solh, D. R. Graham, L. R. Grier, J. Hall, M. S. Harrison, M. T. Herbert, R. C. Hyzy, R. J. Kaner, L. S. Larsen, Ira Leviton, S. C. Matchett, M. H. Metzler, M. L. Morganroth, A. R. Murthy, P. E. Nolan, N. H. Olson, L. B. Palmer, R. G. Postier, D. P. Remy, G. J. Richmond, M. H. Rosenthal, G. Sanchez, R. B. Schechter, S. J. Simon, T. W. Smith, B. Thompson, B. J. White, B. Hafkin, W. M. Todd, J. Timm, K. Hempsall, L. Schuemann

Research output: Contribution to journalArticle

419 Citations (Scopus)

Abstract

Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

Original languageEnglish (US)
Pages (from-to)402-412
Number of pages11
JournalClinical Infectious Diseases
Volume32
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Linezolid
Vancomycin
Double-Blind Method
Multicenter Studies
Pneumonia
Aztreonam
Therapeutics
Oxazolidinones
Safety
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus

ASJC Scopus subject areas

  • Immunology

Cite this

Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., Labrooy, J., Moran, J. L., ... Schuemann, L. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clinical Infectious Diseases, 32(3), 402-412. https://doi.org/10.1086/318486

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia : A randomized, double-blind, multicenter study. / Rubinstein, E.; Cammarata, S. K.; Oliphant, T. H.; Wunderink, R. G.; Labrooy, J.; Moran, J. L.; Richards, B.; Grimard, D.; Landis, S. J.; Rotstein, C.; Chavez, E.; Northland, R.; Triantafilo, V.; Vasquez, P.; Kolek, V.; Kucera, M.; Reiterer, P.; Weidenhoffer, I.; Andrews, C.; McLaren, I.; Street, M.; Ali-Malkkilä, T.; Heikkinen, J.; Kairi, P.; Valtonen, M.; Georges, B.; Holzapfel, L.; Leon, A.; Martin, C. D.; Maurette, P.; Muir, J. F.; Ossart, M.; Veber, B.; Lukacs, J.; Nagy, G.; Rott, Z.; Raz, R.; Riesenberg, K.; Yinnon, A.; Molinari, M.; Castro, G.; Fabian, G.; Gaca, M.; Krawczyk, L.; Malolepszy, J.; Szulc, R.; Wolowicka, L.; Chuchalin, A. G.; Fedorova, T.; Kakhnovskii, I. M.; Novozhenov, V. G.; Sinopalnikov, A. I.; Kilian, J. G.; Michell, W. L.; Sturm, A. W.; Viljoen, J.; Wood, R.; Pueyo, J. M.; Soler-Obradors, M.; Baird, I. M.; Birmingham, M. C.; Bjerke, H. S.; Brown, M. A.; Chow, S. J D; Daniels, R. K.; Dickey, T.; El-Solh, A.; Graham, D. R.; Grier, L. R.; Hall, J.; Harrison, M. S.; Herbert, M. T.; Hyzy, R. C.; Kaner, R. J.; Larsen, L. S.; Leviton, Ira; Matchett, S. C.; Metzler, M. H.; Morganroth, M. L.; Murthy, A. R.; Nolan, P. E.; Olson, N. H.; Palmer, L. B.; Postier, R. G.; Remy, D. P.; Richmond, G. J.; Rosenthal, M. H.; Sanchez, G.; Schechter, R. B.; Simon, S. J.; Smith, T. W.; Thompson, B.; White, B. J.; Hafkin, B.; Todd, W. M.; Timm, J.; Hempsall, K.; Schuemann, L.

In: Clinical Infectious Diseases, Vol. 32, No. 3, 2001, p. 402-412.

Research output: Contribution to journalArticle

Rubinstein, E, Cammarata, SK, Oliphant, TH, Wunderink, RG, Labrooy, J, Moran, JL, Richards, B, Grimard, D, Landis, SJ, Rotstein, C, Chavez, E, Northland, R, Triantafilo, V, Vasquez, P, Kolek, V, Kucera, M, Reiterer, P, Weidenhoffer, I, Andrews, C, McLaren, I, Street, M, Ali-Malkkilä, T, Heikkinen, J, Kairi, P, Valtonen, M, Georges, B, Holzapfel, L, Leon, A, Martin, CD, Maurette, P, Muir, JF, Ossart, M, Veber, B, Lukacs, J, Nagy, G, Rott, Z, Raz, R, Riesenberg, K, Yinnon, A, Molinari, M, Castro, G, Fabian, G, Gaca, M, Krawczyk, L, Malolepszy, J, Szulc, R, Wolowicka, L, Chuchalin, AG, Fedorova, T, Kakhnovskii, IM, Novozhenov, VG, Sinopalnikov, AI, Kilian, JG, Michell, WL, Sturm, AW, Viljoen, J, Wood, R, Pueyo, JM, Soler-Obradors, M, Baird, IM, Birmingham, MC, Bjerke, HS, Brown, MA, Chow, SJD, Daniels, RK, Dickey, T, El-Solh, A, Graham, DR, Grier, LR, Hall, J, Harrison, MS, Herbert, MT, Hyzy, RC, Kaner, RJ, Larsen, LS, Leviton, I, Matchett, SC, Metzler, MH, Morganroth, ML, Murthy, AR, Nolan, PE, Olson, NH, Palmer, LB, Postier, RG, Remy, DP, Richmond, GJ, Rosenthal, MH, Sanchez, G, Schechter, RB, Simon, SJ, Smith, TW, Thompson, B, White, BJ, Hafkin, B, Todd, WM, Timm, J, Hempsall, K & Schuemann, L 2001, 'Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study', Clinical Infectious Diseases, vol. 32, no. 3, pp. 402-412. https://doi.org/10.1086/318486
Rubinstein, E. ; Cammarata, S. K. ; Oliphant, T. H. ; Wunderink, R. G. ; Labrooy, J. ; Moran, J. L. ; Richards, B. ; Grimard, D. ; Landis, S. J. ; Rotstein, C. ; Chavez, E. ; Northland, R. ; Triantafilo, V. ; Vasquez, P. ; Kolek, V. ; Kucera, M. ; Reiterer, P. ; Weidenhoffer, I. ; Andrews, C. ; McLaren, I. ; Street, M. ; Ali-Malkkilä, T. ; Heikkinen, J. ; Kairi, P. ; Valtonen, M. ; Georges, B. ; Holzapfel, L. ; Leon, A. ; Martin, C. D. ; Maurette, P. ; Muir, J. F. ; Ossart, M. ; Veber, B. ; Lukacs, J. ; Nagy, G. ; Rott, Z. ; Raz, R. ; Riesenberg, K. ; Yinnon, A. ; Molinari, M. ; Castro, G. ; Fabian, G. ; Gaca, M. ; Krawczyk, L. ; Malolepszy, J. ; Szulc, R. ; Wolowicka, L. ; Chuchalin, A. G. ; Fedorova, T. ; Kakhnovskii, I. M. ; Novozhenov, V. G. ; Sinopalnikov, A. I. ; Kilian, J. G. ; Michell, W. L. ; Sturm, A. W. ; Viljoen, J. ; Wood, R. ; Pueyo, J. M. ; Soler-Obradors, M. ; Baird, I. M. ; Birmingham, M. C. ; Bjerke, H. S. ; Brown, M. A. ; Chow, S. J D ; Daniels, R. K. ; Dickey, T. ; El-Solh, A. ; Graham, D. R. ; Grier, L. R. ; Hall, J. ; Harrison, M. S. ; Herbert, M. T. ; Hyzy, R. C. ; Kaner, R. J. ; Larsen, L. S. ; Leviton, Ira ; Matchett, S. C. ; Metzler, M. H. ; Morganroth, M. L. ; Murthy, A. R. ; Nolan, P. E. ; Olson, N. H. ; Palmer, L. B. ; Postier, R. G. ; Remy, D. P. ; Richmond, G. J. ; Rosenthal, M. H. ; Sanchez, G. ; Schechter, R. B. ; Simon, S. J. ; Smith, T. W. ; Thompson, B. ; White, B. J. ; Hafkin, B. ; Todd, W. M. ; Timm, J. ; Hempsall, K. ; Schuemann, L. / Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia : A randomized, double-blind, multicenter study. In: Clinical Infectious Diseases. 2001 ; Vol. 32, No. 3. pp. 402-412.
@article{282799e0acc54bcab0b27ff67af37bc9,
title = "Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study",
abstract = "Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4{\%}] of 107 for linezolid vs. 62 [68.1{\%}] of 91 for vancomycin) and microbiological success rates (36 [67.9{\%}] of 53 vs. 28 [71.8{\%}] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.",
author = "E. Rubinstein and Cammarata, {S. K.} and Oliphant, {T. H.} and Wunderink, {R. G.} and J. Labrooy and Moran, {J. L.} and B. Richards and D. Grimard and Landis, {S. J.} and C. Rotstein and E. Chavez and R. Northland and V. Triantafilo and P. Vasquez and V. Kolek and M. Kucera and P. Reiterer and I. Weidenhoffer and C. Andrews and I. McLaren and M. Street and T. Ali-Malkkil{\"a} and J. Heikkinen and P. Kairi and M. Valtonen and B. Georges and L. Holzapfel and A. Leon and Martin, {C. D.} and P. Maurette and Muir, {J. F.} and M. Ossart and B. Veber and J. Lukacs and G. Nagy and Z. Rott and R. Raz and K. Riesenberg and A. Yinnon and M. Molinari and G. Castro and G. Fabian and M. Gaca and L. Krawczyk and J. Malolepszy and R. Szulc and L. Wolowicka and Chuchalin, {A. G.} and T. Fedorova and Kakhnovskii, {I. M.} and Novozhenov, {V. G.} and Sinopalnikov, {A. I.} and Kilian, {J. G.} and Michell, {W. L.} and Sturm, {A. W.} and J. Viljoen and R. Wood and Pueyo, {J. M.} and M. Soler-Obradors and Baird, {I. M.} and Birmingham, {M. C.} and Bjerke, {H. S.} and Brown, {M. A.} and Chow, {S. J D} and Daniels, {R. K.} and T. Dickey and A. El-Solh and Graham, {D. R.} and Grier, {L. R.} and J. Hall and Harrison, {M. S.} and Herbert, {M. T.} and Hyzy, {R. C.} and Kaner, {R. J.} and Larsen, {L. S.} and Ira Leviton and Matchett, {S. C.} and Metzler, {M. H.} and Morganroth, {M. L.} and Murthy, {A. R.} and Nolan, {P. E.} and Olson, {N. H.} and Palmer, {L. B.} and Postier, {R. G.} and Remy, {D. P.} and Richmond, {G. J.} and Rosenthal, {M. H.} and G. Sanchez and Schechter, {R. B.} and Simon, {S. J.} and Smith, {T. W.} and B. Thompson and White, {B. J.} and B. Hafkin and Todd, {W. M.} and J. Timm and K. Hempsall and L. Schuemann",
year = "2001",
doi = "10.1086/318486",
language = "English (US)",
volume = "32",
pages = "402--412",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia

T2 - A randomized, double-blind, multicenter study

AU - Rubinstein, E.

AU - Cammarata, S. K.

AU - Oliphant, T. H.

AU - Wunderink, R. G.

AU - Labrooy, J.

AU - Moran, J. L.

AU - Richards, B.

AU - Grimard, D.

AU - Landis, S. J.

AU - Rotstein, C.

AU - Chavez, E.

AU - Northland, R.

AU - Triantafilo, V.

AU - Vasquez, P.

AU - Kolek, V.

AU - Kucera, M.

AU - Reiterer, P.

AU - Weidenhoffer, I.

AU - Andrews, C.

AU - McLaren, I.

AU - Street, M.

AU - Ali-Malkkilä, T.

AU - Heikkinen, J.

AU - Kairi, P.

AU - Valtonen, M.

AU - Georges, B.

AU - Holzapfel, L.

AU - Leon, A.

AU - Martin, C. D.

AU - Maurette, P.

AU - Muir, J. F.

AU - Ossart, M.

AU - Veber, B.

AU - Lukacs, J.

AU - Nagy, G.

AU - Rott, Z.

AU - Raz, R.

AU - Riesenberg, K.

AU - Yinnon, A.

AU - Molinari, M.

AU - Castro, G.

AU - Fabian, G.

AU - Gaca, M.

AU - Krawczyk, L.

AU - Malolepszy, J.

AU - Szulc, R.

AU - Wolowicka, L.

AU - Chuchalin, A. G.

AU - Fedorova, T.

AU - Kakhnovskii, I. M.

AU - Novozhenov, V. G.

AU - Sinopalnikov, A. I.

AU - Kilian, J. G.

AU - Michell, W. L.

AU - Sturm, A. W.

AU - Viljoen, J.

AU - Wood, R.

AU - Pueyo, J. M.

AU - Soler-Obradors, M.

AU - Baird, I. M.

AU - Birmingham, M. C.

AU - Bjerke, H. S.

AU - Brown, M. A.

AU - Chow, S. J D

AU - Daniels, R. K.

AU - Dickey, T.

AU - El-Solh, A.

AU - Graham, D. R.

AU - Grier, L. R.

AU - Hall, J.

AU - Harrison, M. S.

AU - Herbert, M. T.

AU - Hyzy, R. C.

AU - Kaner, R. J.

AU - Larsen, L. S.

AU - Leviton, Ira

AU - Matchett, S. C.

AU - Metzler, M. H.

AU - Morganroth, M. L.

AU - Murthy, A. R.

AU - Nolan, P. E.

AU - Olson, N. H.

AU - Palmer, L. B.

AU - Postier, R. G.

AU - Remy, D. P.

AU - Richmond, G. J.

AU - Rosenthal, M. H.

AU - Sanchez, G.

AU - Schechter, R. B.

AU - Simon, S. J.

AU - Smith, T. W.

AU - Thompson, B.

AU - White, B. J.

AU - Hafkin, B.

AU - Todd, W. M.

AU - Timm, J.

AU - Hempsall, K.

AU - Schuemann, L.

PY - 2001

Y1 - 2001

N2 - Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

AB - Linezolid, the first oxazolidinone, is active against gram-positive bacteria, including multidrug-resistant strains. This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia. A total of 203 patients received intravenous linezolid, 600 mg twice daily, plus aztreonam, and 193 patients received vancomycin, 1 g intravenously twice daily, plus aztreonam for 7-21 days. Clinical and microbiological outcomes were evaluated at test of cure 12-28 days after treatment. Clinical cure rates (71 [66.4%] of 107 for linezolid vs. 62 [68.1%] of 91 for vancomycin) and microbiological success rates (36 [67.9%] of 53 vs. 28 [71.8%] of 39, respectively) for evaluable patients were equivalent between treatment groups. Eradication rates of methicillin-resistant Staphylococcus aureus and safety evaluations were similar between treatment groups. Resistance to either treatment was not detected. Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=0035112879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035112879&partnerID=8YFLogxK

U2 - 10.1086/318486

DO - 10.1086/318486

M3 - Article

C2 - 11170948

AN - SCOPUS:0035112879

VL - 32

SP - 402

EP - 412

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -